ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 250 shares of the firm's stock in a transaction on Friday, April 12th. The stock was sold at an average price of $67.79, for a total value of $16,947.50. Following the completion of the transaction, the vice president now owns 59,731 shares in the company, valued at approximately $4,049,164.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Meredith Cook also recently made the following trade(s):
- On Tuesday, February 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $56.04, for a total transaction of $14,010.00.
ANI Pharmaceuticals Price Performance
Shares of ANIP opened at $66.30 on Tuesday. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.40 billion, a PE ratio of 78.93 and a beta of 0.79. ANI Pharmaceuticals, Inc. has a 12-month low of $36.99 and a 12-month high of $70.81. The business has a 50-day simple moving average of $64.23 and a two-hundred day simple moving average of $58.42.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Biden out June 13; Kamala won’t replace him?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
Several research firms recently issued reports on ANIP. HC Wainwright increased their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a "buy" rating in a research report on Monday, March 4th. Capital One Financial assumed coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an "overweight" rating and a $80.00 price objective on the stock. Guggenheim boosted their target price on ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a "buy" rating in a research note on Tuesday, March 5th. Finally, Truist Financial raised their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, March 1st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of "Buy" and an average price target of $80.00.
Check Out Our Latest Report on ANI Pharmaceuticals
Hedge Funds Weigh In On ANI Pharmaceuticals
Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its holdings in ANI Pharmaceuticals by 93.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company's stock valued at $30,000 after purchasing an additional 248 shares during the period. BluePath Capital Management LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at about $34,000. Pacer Advisors Inc. acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $41,000. Point72 Asset Management L.P. raised its position in shares of ANI Pharmaceuticals by 60.0% during the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company's stock worth $42,000 after acquiring an additional 291 shares during the last quarter. Finally, Coppell Advisory Solutions LLC acquired a new position in shares of ANI Pharmaceuticals in the second quarter worth approximately $44,000. Institutional investors own 76.05% of the company's stock.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
